Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780089 · ClinicalTrials.gov registry record
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 408
- Enrollment target
NCT02780089 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 408 participants.
The verdict
NCT02780089 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 408 participants
- Enrollment target
Study Summary
This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2015-10-23 |
| Est. Completion | 2020-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780089
The ClinicalTrials.gov registry entry for NCT02780089 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02780089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780089 about?
NCT02780089 is a clinical study titled "Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study". This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.
What is the current status of trial NCT02780089?
This trial is currently completed. The enrollment target is 408 participants. The study started on 2015-10-23. Estimated completion is 2020-09-08.
Who is sponsoring clinical trial NCT02780089?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.